In addition, cancer immunotherapies, such as programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint inhibitors, are being developed as promising alternative strategies for treating patients with advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.